Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.28 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 281.58 |
| Open | 284.2 |
| 1-Year Change | -9.33% |
| Day's Range | 281.42 - 284.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 29, 2025 | 281.58 | 1.62 | 0.58% | 279.96 | 282.98 | 279.06 |
| Jan 28, 2025 | 280.01 | -0.06 | -0.02% | 280.07 | 282.95 | 279.90 |
| Jan 27, 2025 | 282.78 | 6.17 | 2.23% | 276.61 | 283.15 | 275.45 |
| Jan 24, 2025 | 275.20 | 0.10 | 0.04% | 275.10 | 277.04 | 273.34 |
| Jan 23, 2025 | 277.59 | 5.42 | 1.99% | 272.17 | 277.72 | 271.39 |
| Jan 22, 2025 | 272.88 | 0.55 | 0.20% | 272.33 | 274.81 | 272.15 |
| Jan 21, 2025 | 274.55 | 2.60 | 0.96% | 271.95 | 276.35 | 269.73 |
| Jan 17, 2025 | 271.60 | -2.25 | -0.82% | 273.85 | 274.26 | 269.81 |
| Jan 16, 2025 | 269.12 | 1.17 | 0.44% | 267.95 | 270.05 | 267.07 |
| Jan 15, 2025 | 268.76 | 0.12 | 0.04% | 268.64 | 272.68 | 268.09 |
| Jan 14, 2025 | 267.03 | -2.74 | -1.02% | 269.77 | 270.85 | 264.82 |
| Jan 13, 2025 | 269.96 | 8.05 | 3.07% | 261.91 | 270.34 | 260.95 |
| Jan 10, 2025 | 261.80 | 0.97 | 0.37% | 260.83 | 264.20 | 260.45 |
| Jan 8, 2025 | 263.87 | 2.10 | 0.80% | 261.77 | 264.14 | 259.54 |
| Jan 7, 2025 | 261.40 | 2.86 | 1.11% | 258.54 | 264.87 | 258.14 |
| Jan 6, 2025 | 258.40 | 0.15 | 0.06% | 258.25 | 260.99 | 256.96 |
| Jan 3, 2025 | 260.42 | 0.64 | 0.25% | 259.78 | 261.94 | 258.53 |
| Jan 2, 2025 | 259.07 | -2.94 | -1.12% | 262.01 | 263.20 | 258.14 |
| Dec 31, 2024 | 260.45 | 0.25 | 0.10% | 260.20 | 261.19 | 258.76 |
| Dec 30, 2024 | 259.21 | -1.89 | -0.72% | 261.10 | 261.40 | 258.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com